The outpatient medical care in patients with chronic diseases under dispensary supervision in the conditions of the COVID-19 pandemic. Temporary guidelines. Version 2

Драпкина, О. М.; Drozdova, L. Yu.; Авдеев, С. Н.; Boytsov, S. А.; Иванова, Екатерина; Каприн, А. Д.; Kunaeva, T. A.; Лавренова, Е. А.; Liusan, M. A.; Маев, И. В.; Rakowskaya, J. S.; Samorodskaya, I. V.; Чесникова, А. И.; Shepel, R. N.

doi:10.15829/1728-8800-2021-3172

Cited by 13 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The variety of specialists involved in the development of these guidelines was better than in all other identified CPGs. A similar score (65%) for this domain was received by the ROPNIZ CPGs [15] and MGNOT [20] (See Appendix H-Section assessment results STAKEHOLDER INVOLVEMENT). These three CPGs received similar comments.…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 78%

“…The highest score (49%) for the domain Rigour and Development was attributed to the ROPNIZ [15] CPG (Appendix H). Section assessment results RIGOUR OF DEVELOP-MENT).…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

“…Section assessment results RIGOUR OF DEVELOP-MENT). Even though this CPG had a high score, there were comments for this domain: the ROPNIZ [15] CPG did not include the methods for formulating the recommendations and these aren't clearly described, and the opinion of external experts and the update procedure are not described. It did not include a method for reviewing the strengths and limitations of the evidence (such as GRADE), or a Delphi method for formulating the recommendations.…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

See 2 more Smart Citations

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Baybulatova,

Chenkurov,

Korovyakova

et al. 2023

Pharmacoepidemiology

View full text Add to dashboard Cite

Background: The coronavirus pandemic has led to the creation of clinical guidelines by a large number of professional medical communities. However, the quality and methodology of development of Russian clinical guidelines has been little studied. The continued relevance of studying the use of DOACs (Direct oral anticoagulants) in patients with COVID-19 was the basis for conducting this study. Aim: The objective of this study was to assess DOAC consumption and expenditure in the Russian Federation during the COVID-19 pandemic and to analyze whether it was supported by the domestic evidence base for the use of DOACs in COVID-19 patients through identifying all publicly available Russian-produced CPGs (Clinical practice guidelines) for the treatment of COVID-19 and assessing their quality as the source of recommendations for the use of oral anticoagulants for the prevention of thrombotic complications in COVID-19 patients. We searched Russian databases for CPGs, published between 2020 and 2023. We identified seven relevant documents that met our inclusion criteria. Three authors analyzed Russian clinical guidelines using an AGREE II questionnaire. We calculated DOAC DDD (defined daily dose) consumption according to Russian clinical guidelines and DDD consumption in patients with COVID-19 for the period 2020–2022. Results: Seven clinical CPGs were analyzed with the AGREE II tool. It was revealed that experts gave the highest scores for the sections on scope and purpose (from 62.98% to 100%), and clarity of presentation (from 96.30% to 100%). The lowest scores were given for the sections on stakeholder involvement (33.33% to 64.81%), rigour of development (from 0% to 49.31%), applicability (from 23.61% to 50%), and editorial independence (from 0% to 50%). When comparing the total score, it was found that two clinical guidelines received the highest scores—ROPNIZ (Livzan), and ROPNIZ (Drapkina). The minimum score was registered with the NIIOZMM (Khripun) clinical guideline. No guideline received a total score of more than 70%. According to clinical recommendations, the consumption of apixaban and rivaroxaban is 15 DDD (30-day course of therapy), or 22.5 DDD (45-day course of therapy). Consumption of apixaban in the Russian Federation in 2020 and 2021 corresponds to the indicators presented in clinical recommendations (in 2020—26.59 DDD per patient with COVID-19; in 2021—15.75 DDD per patient with COVID-19), and in 2022—10.67 DDD, which is below the recommended values. In 2020, consumption of rivaroxaban in the Russian Federation was 26.59 which corresponds to data from clinical recommendations; in 2021, consumption decreased to 7.87 DDD; in 2022 it decreased to 5.48 DDD, which is 2.74 times less than recommended. Conclusions: Analysis of seven clinical recommendations revealed that such sections of clinical recommendations as scope, purpose, and clarity of presentation had the highest degree of assessment in accordance with AGREE II. The lowest scores were given for the sections on stakeholder involvement, rigour of development, applicability, and editorial independence. When comparing the total score, it was found that two clinical guidelines received the highest scores—the Russian Society for the Prevention of Non-communicable Diseases (Livzan), and the Russian Society for the Prevention of Non-communicable Diseases (Drapkina). The minimum score was registered with the Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department clinical guideline. No guideline received a total score of more than 70%. During the pandemic, the highest DDD consumption of DOACs was in 2020, which exceeded the DOACs’ recommended DDD by Russian clinical guidelines. DOAC consumption had decreased by 2022. There was a decrease in the consumption of rivaroxaban, with an increase in apixaban’s share in the structure of DOAC consumption during the coronavirus pandemic. Obtained data indicate that in 2021 the apixaban consumption in the Russian Federation corresponded to the recommended DDD in the national guidelines, which indicates the most correct use of apixaban according to Russian GPGs.

show abstract

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 78%

“…The highest score (49%) for the domain Rigour and Development was attributed to the ROPNIZ [15] CPG (Appendix H). Section assessment results RIGOUR OF DEVELOP-MENT).…”

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

Section: Results Of Cpgs Assessment Domain Scoresmentioning

confidence: 99%

See 1 more Smart Citation

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Baybulatova,

Chenkurov,

Korovyakova

et al. 2023

Pharmacoepidemiology

View full text Add to dashboard Cite

show abstract

“…Основной проблемой большинства публикаций является малая выборка пациентов, и, как следствие, низкая доказательность информации. Кроме того, отмечается недостаточное количество публикаций, посвященных вопросам вакцинопрофилактики [26,27]. Однако в этом вопросе имеется определенная сложность: эффективность вакцины всегда изучается по отношению к циркулирующему штамму вируса в данный момент.…”

Section: Discussionunclassified

Russian-language publication activity of medical researchers in during the COVID-19 pandemic: “post-COVID-19 syndrome”

Kim¹,

Drapkina²,

Rodionova³

2022

Cardiovasc Ther Prev

Self Cite

View full text Add to dashboard Cite

Aim. To study the dynamics and pattern of publications in Russian on post-COVID-19 syndrome (PCS) in order to assess the completeness of information and identify medical specialties with its most active investigation in Russia.Material and methods. The search for publications was carried out in the database of the largest digital scientific library in Russia Elibrary.ru from February 1, 2021 to February 1, 2022. The study included publicly available medical publications on the consequences of coronavirus disease 2019 (COVID-19) in Russian. Publications were classified according to subject matter, study design, and evidence hierarchy. The data obtained is reflected using integers, percentages and graphs.Results. The study included 478 publications, of which 196 (41%) presented data from original studies, while 269 (56,3%) reflected the results of existing sources. Expert community documents accounted for 2,7%. In terms of study design, most of original studies described case series (37,2%) and individual case reports (22,4%). Casecontrol studies accounted for 20,4%, cross-sectional studies — 8,7%, prospective cohort studies — 3,6%, randomized clinical trials — 1,5%, and systematic reviews — 1%. In addition, 5,1% of publications were devoted to preclinical studies, mathematical models and various methodological aspects. By topic, the largest number of publications noted cardiovascular (12,2%) and neurological manifestations of PCS (12,2%). Furthermore, 23,5% of publications described the course of PCS in specific groups of patients, particular issues of COVID-19 consequences, and healthcare management problems. We also revealed that 11,7% of publications were devoted to general rehabilitation, 71% — to imaging diagnostics, 5,6% — to herd immunity to the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARSCoV-2), and 5,6% — to PCS features in children. The smallest number of publications considered mental (5,1%), gastroenterological (4,6%), pharmacological (4,6%), rheumatological (4%) and pulmonological aspects of PCS.Conclusion. The dynamics and pattern of publications on COVID-19 in Russian are generally consistent with global trends and reflect the natural consequences of the pandemic. This analysis of publications on PCS showed that the most in-demand specializations in this filed are cardiology, neurology, and rehabilitation.

show abstract

“…No 173н диспансерное наблюдение при хроническом атрофическом фундальном и мультифокальном гастрите предусматривает прием (осмотр, консультация) врача-гастроэнтеролога 1 раз в год, прием (осмотр, консультация) врача-онколога по медицинским показаниям c контролем морфологических изменений по данным высокоточной ЭГДС с биопсией. Рекомендуемый интервал эндоскопического наблюдения определен как 1 раз в 1-2 года [31,32].…”

Section: клинический примерunclassified

Autoimmune gastritis and stomach cancer: assessing the risks

Gubanova,

Livzan,

Krolevets

et al. 2023

jour

View full text Add to dashboard Cite

The purpose of this publication is to systematize available data on the risks of developing stomach cancer in patients with a chronic autoimmune gastritis with a demonstration of the clinical case of a patient with a chronic autoimmune gastritis and a neuroendocrine gastric tumor of the type 1. Discussion: the article discusses the risks of stomach cancer in patients with chronic autoimmune gastritis. A mechanism for the formation of a neuroendocrine gastric tumor of the type 1, associated with autoimmune gastritis, is given. A clinical example of a patient with a long history of dyspepsia, the presence of concomitant changes in the results of laboratory tests, describes an algorithm for diagnosis of autoimmune gastritis and associated neuroendocrine tumors. The risks of the development in patients with autoimmune gastritis of formidable complications as an adenocarcinoma of the stomach are considered. Conclusion: Chronic autoimmune gastritis is a precancerous diseases of the stomach, with the progressive atrophy of the gastric body mucosa, and associated with an increased risk of developing neuroendocrine gastric tumor of the type 1 and adenocarcinoma of the stomach. Patients with autoimmune gastritis need dynamic outpatient observation, with endoscopic control and assessment of the degree and stage of gastritis in OLGA system, with immunogistochemistry to evaluate the risks of stomach cancer and timely implementation of the necessary measures of carcinoprection.

show abstract

The outpatient medical care in patients with chronic diseases under dispensary supervision in the conditions of the COVID-19 pandemic. Temporary guidelines. Version 2

Cited by 13 publications

References 14 publications

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Direct Oral Anticoagulants’ Consumption and Expenditure in the COVID-19 Pandemic in Russia and Clinical Practice Guidelines for Their Use

Russian-language publication activity of medical researchers in during the COVID-19 pandemic: “post-COVID-19 syndrome”

Autoimmune gastritis and stomach cancer: assessing the risks

Contact Info

Product

Resources

About